奧洛茲美醫療 HALO 深 滬
等待開盤 09-10 09:30:00 美东时间
76.07
+0.220
+0.29%
華盛通- 最 高76.10
- 今 開76.00
- 成交量 144.97万股
- 最 低 74.85
- 昨 收 75.85
- 總市值 89.00亿
- 52周最高 76.28
- 市盈率 靜 22.17
- 換手率 1.24%
- 52周最低 42.01
- 委 比 49.98%
- 總股本 1.17亿
- 歷史最高 76.28
- 量 比 0.64
- 振 幅 1.65%
- 歷史最低 3.86
- 每 手 1
- 風險率 6.37%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多What 7 Analyst Ratings Have To Say About Halozyme Therapeutics
During the last three months, 7 analysts shared their evaluations of Halozyme T...
08-19 04:01
Morgan Stanley Maintains Overweight on Halozyme Therapeutics, Raises Price Target to $80
Morgan Stanley analyst Vikram Purohit maintains Halozyme Therapeutics (NASDAQ:HALO) with a Overweight and raises the price target from $75 to $80.
08-18 20:52
Luminar Technologies Q2 FY2025 Earnings Call Transcript
Luminar stock drops after earnings. Here's the Luminar Technologies Q2 FY2025 earnings call transcript.
08-13 06:51
A Glimpse of Roivant Sciences's Earnings Potential
Roivant Sciences (NASDAQ:ROIV) is preparing to release its quarterly earnings o...
08-08 22:05
美股大行评级 | DoorDash获上调目标价从230美元升至300美元； 摩根大通上调Shopify目标价从115美元升至179美元
今日重点评级关注：HC Wainwright & Co.：维持FibroGen"买入"评级，目标价从10美元升至43美元；摩根大通：维持Cogent Biosciences"超配"评级，目标价从29美元升至30美元
08-08 09:34
What Does the Market Think About Halozyme Therapeutics?
Halozyme Therapeutics's (NYSE:HALO) short percent of float has fallen 5.58% sin...
08-08 02:00
Halozyme up after guidance raise, Morgan Stanley upgrade
Halozyme (NASDAQ:HALO) stock rose on Wednesday after the company raised 2025 guidance, prompting a rating upgrade by Morgan Stanley. The company raised 2025 revenue in the range between $1,275M and $1...
08-06 23:35
Morgan Stanley Upgrades Halozyme Therapeutics to Overweight, Raises Price Target to $75
Morgan Stanley analyst Vikram Purohit upgrades Halozyme Therapeutics (NASDAQ:HALO) from Equal-Weight to Overweight and raises the price target from $62 to $75.
08-06 19:19
Halozyme shares are trading higher after the company raised FY25 guidance.
Halozyme shares are trading higher after the company raised FY25 guidance.
08-06 04:03
CORRECTION: Halozyme Therapeutics Q2 Adj. EPS $1.54 Beats $1.23 Estimate, Sales $325.719M Beat $281.588M Estimate
Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $1.54 per share which beat the analyst consensus estimate of $1.23 by 25.2 percent. This is a 69.23 percent increase over earnings of $0.91 per share
08-06 04:03
